The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP 1 Drugs, and a Compounding Pharmacy Operating Without Control BPC 157: Miracle Healing Peptide or Hidden Danger? FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea